Orotsaeureanhydrid | 4449-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Orotsaeureanhydrid
• 英文别名: 2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid anhydride；(2,4-dioxo-1H-pyrimidine-6-carbonyl) 2,4-dioxo-1H-pyrimidine-6-carboxylate
• CAS: 4449-69-8
• 化学式: C₁₀H₆N₄O₇
• 分子量: 294.18
• InChiKey: QKIIRDJTYZQUJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] CRYSTAL FORMS OF AMINO LIPIDS<br/>[FR] FORMES CRISTALLINES D'AMINOLIPIDES
  申请人：MODERNATX INC

  公开号：WO2018170322A1

  公开（公告）日：2018-09-20

  Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate ("Compound 1"), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate ("Compound 2"),(3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate ("Compound 3"), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate ("MC3"), and related compositions and methods.

  本文介绍了四种化合物的新型固态形式：(1) 庚十七烷-9-基8-((2-羟乙基)氨基)辛酸酯（“化合物1”），(2) 庚十七烷-9-基8-((2-羟乙基)(6-氧代-6-(十一烷氧基)己基)氨基)辛酸酯（“化合物2”），(3) 庚十七烷-9-基8-((2-羟乙基)(8-(壬氧基)-8-氧代辛基)氨基)辛酸酯（“化合物3”），以及(6Z,9Z,28Z,31Z)-庚三十七碳六烯-6,9,28,31-四烯-19-基4-(二甲氨基)丁酸酯（“MC3”）及其相关组合物和方法。
• ARTERIAL OXYGEN SATURATION DEGREE IMPROVER
  申请人：Furukawa Research Office Co., Ltd.

  公开号：EP3622957A1

  公开（公告）日：2020-03-18

  The present invention provides an improving agent that suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation, and that can be ingested by a relatively simple method and has excellent immediate effectivity and persistence. In the improving agent of the invention, orotic acid or a salt thereof prepared to be absorbed into the body via oral mucosa is an active ingredient. Ingestion of the improving agent of the present invention so that the agent is absorbed in the body via oral mucosa can suppress a decrease in arterial oxygen saturation or can increase decreased arterial oxygen saturation. The improving agent is effective for improvement or prevention of a symptom or disease related to a decrease in arterial oxygen saturation, such as exercise, alcohol drinking, a decrease in oxygen concentration in air, reduced cardiopulmonary function, and respiratory arrest, and a symptom or disease caused by hypoxia, in particular, for prevention of an increase in uric acid level.

  本发明提供了一种改善剂，可抑制动脉血氧饱和度的降低或增加降低的动脉血氧饱和度，并可通过相对简单的方法摄入，具有良好的即时效果和持久性。在本发明的改良剂中，可通过口腔粘膜被人体吸收的奥罗酸或其盐类是一种活性成分。摄入本发明的改善剂，使其通过口腔黏膜被人体吸收，可抑制动脉血氧饱和度的降低，或增加动脉血氧饱和度的降低。本发明的改善剂可有效改善或预防与动脉血氧饱和度降低有关的症状或疾病，如运动、饮酒、空气中氧浓度降低、心肺功能减退和呼吸停止，以及缺氧引起的症状或疾病，特别是可预防尿酸水平升高。
• Arterial oxygen saturation degree improver
  申请人：FURUKAWA RESEARCH OFFICE CO., LTD.

  公开号：US11331318B2

  公开（公告）日：2022-05-17

  The present invention provides an agent that suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation, and that can be ingested by a relatively simple method and has excellent immediate effectivity and persistence. The agent of the invention comprises orotic acid or a salt thereof as an active ingredient, which is absorbed into the body via oral mucosa. When the agent is absorbed in the body via oral mucosa it suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation. The agent is effective for improvement or prevention of a symptom or disease related to a decrease in arterial oxygen saturation, such as exercise, alcohol drinking, a decrease in oxygen concentration in air, reduced cardiopulmonary function, and respiratory arrest, and a symptom or disease caused by hypoxia, in particular, for prevention of an increase in uric acid level.

  本发明提供了一种可抑制动脉血氧饱和度下降或增加下降的动脉血氧饱和度的药剂，该药剂可通过相对简单的方法摄入，并具有极佳的即时有效性和持久性。本发明的制剂包括作为活性成分的奥罗酸或其盐，可通过口腔黏膜被人体吸收。当药剂通过口腔黏膜被人体吸收后，它能抑制动脉血氧饱和度的降低或增加动脉血氧饱和度的降低。该制剂可有效改善或预防与动脉血氧饱和度降低有关的症状或疾病，如运动、饮酒、空气中氧浓度降低、心肺功能减退和呼吸停止，以及缺氧引起的症状或疾病，特别是可预防尿酸水平升高。
• Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen
  申请人：Kurek Itzhak

  公开号：US20190214145A1

  公开（公告）日：2019-07-11

  Disclosed are methods and systems for building a database of metabolite profiles correlated with disease states and treatment regiments, then defining an individual patient's metabolite profile, and then screening the patient's profile against the database to recommend potential effective treatment regimens.
• Arterial Oxygen Saturation Degree Improver
  申请人：FURUKAWA RESEARCH OFFICE CO., LTD.

  公开号：US20200155553A1

  公开（公告）日：2020-05-21

  The present invention provides an agent that suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation, and that can be ingested by a relatively simple method and has excellent immediate effectivity and persistence. The agent of the invention comprises orotic acid or a salt thereof as an active ingredient, which is absorbed into the body via oral mucosa. When the agent is absorbed in the body via oral mucosa it suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation. The agent is effective for improvement or prevention of a symptom or disease related to a decrease in arterial oxygen saturation, such as exercise, alcohol drinking, a decrease in oxygen concentration in air, reduced cardiopulmonary function, and respiratory arrest, and a symptom or disease caused by hypoxia, in particular, for prevention of an increase in uric acid level.